CFTR and cystic fibrosis: Gene editing technologies, particularly CRISPR/Cas9, are essential for modeling lung organoids in CF, as they can effectively correct the CFTR gene and restore chloride ion secretion in patient-derived organoids, paving the way for personalized gene therapy (62–64).